Skip to main content
SpringerLink
Log in

Statin-Associated Autoimmune Myopathy and Other Forms of Myositis

  • Chapter
  • First Online:
Statin-Associated Muscle Symptoms

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 468 Accesses

Abstract

The autoimmune myopathies are a heterogenous family of diseases characterized by weakness, elevated muscle enzymes, and abnormal muscle biopsies. Immune-mediated necrotizing myopathy (IMNM), dermatomyositis, the antisynthetase syndrome, and inclusion body myositis are the four main types of autoimmune myopathy. Statin-associated autoimmune myopathy is a subtype of IMNM that can occur as a rare side effect of statin treatment and is diagnosed based on the presence of autoantibodies recognizing HMG-CoA reductase, the pharmacologic target of statins. This chapter will focus on the clinical features, risk factors, management, and pathogenesis of the autoimmune myopathies, with an emphasis on statin-associated autoimmune myopathy. The autoimmune myopathies not associated with statins are also presented to help clinicians differentiate these myopathies from statin-associated autoimmune myopathy and to decide when statins may be used in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816–28.

    Article  PubMed  Google Scholar 

  2. Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol. 2018;75(12):1528–37.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374(7):664–9.

    Article  CAS  PubMed  Google Scholar 

  4. Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Immune-Mediated Necrotizing Myopathies Working G. 224th ENMC international workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscul Disord. 2018;28(1):87–99.

    Article  PubMed  Google Scholar 

  5. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Tiniakou E, Pinal-Fernandez I, Lloyd TE, Albayda J, Paik J, Werner JL, et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford). 2017;56(5):787–94.

    CAS  Google Scholar 

  7. Mammen AL, Gaudet D, Brisson D, Christopher-Stine L, Lloyd TE, Leffell MS, et al. Increased frequency of DRB1∗11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res. 2012;64(8):1233–7.

    CAS  Google Scholar 

  8. Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, et al. Association of Anti-3-Hydroxy-3-Methylglutaryl-coenzyme A reductase autoantibodies with DRB1∗07:01 and severe myositis in juvenile myositis patients. Arthritis Care Res. 2017;69(7):1088–94.

    Article  CAS  Google Scholar 

  9. Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine. 2014;93(3):150–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Klein M, Mann H, Plestilova L, Zamecnik J, Betteridge Z, McHugh N, et al. Increasing incidence of immune-mediated necrotizing myopathy: single-Centre experience. Rheumatology (Oxford). 2015;54:2010.

    Article  CAS  Google Scholar 

  11. Basharat P, Lahouti AH, Paik JJ, Albayda J, Pinal-Fernandez I, Bichile T, et al. Statin-induced anti-HMGCR-associated myopathy. J Am Coll Cardiol. 2016;68(2):234–5.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Ge Y, Lu X, Peng Q, Shu X, Wang G. Clinical characteristics of Anti-3-Hydroxy-3-Methylglutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. PLoS One. 2015;10(10):e0141616.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Barbacki A, Fallavollita SA, Karamchandani J, Hudson M. Immune-mediated necrotizing myopathy and dietary sources of statins. Ann Intern Med. 2018;168(12):893–904.

    Article  PubMed  Google Scholar 

  14. Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015;373(17):1680–2.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Tiniakou E, Rivera E, Mammen AL, Christopher-Stine L. Use of Proprotein convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors in statin-associated immune mediated necrotizing myopathy: a case-series. Arthritis Rheumatol. 2019;71:1723.

    Article  CAS  PubMed  Google Scholar 

  16. Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum. 2012;64(12):4087–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Allenbach Y, Arouche-Delaperche L, Preusse C, Radbruch H, Butler-Browne G, Champtiaux N, et al. Necrosis in anti-SRP(+) and anti-HMGCR(+)myopathies: role of autoantibodies and complement. Neurology. 2018;90(6):e507–e17.

    Article  CAS  PubMed  Google Scholar 

  18. Bergua C, Chiavelli H, Allenbach Y, Arouche-Delaperche L, Arnoult C, Bourdenet G, et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis. 2019;78(1):131–9.

    Article  CAS  PubMed  Google Scholar 

  19. Pinal-Fernandez I, Parks C, Werner JL, Albayda J, Paik J, Danoff SK, et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res. 2017;69(2):263–70.

    Article  CAS  Google Scholar 

  20. Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, Takayama K, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016;87:1038.

    Article  PubMed  Google Scholar 

  21. Rothwell S, Chinoy H, Lamb JA, Miller FW, Rider LG, Wedderburn LR, et al. Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann Rheum Dis. 2019;78:996.

    Article  CAS  PubMed  Google Scholar 

  22. Leff RL, Burgess SH, Miller FW, Love LA, Targoff IN, Dalakas MC, et al. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. Arthritis Rheum. 1991;34(11):1391–6.

    Article  CAS  PubMed  Google Scholar 

  23. Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res. 2010;62(9):1328–34.

    Article  CAS  Google Scholar 

  24. Benveniste O, Drouot L, Jouen F, Charuel JL, Bloch-Queyrat C, Behin A, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum. 2011;63(7):1961–71.

    Article  CAS  PubMed  Google Scholar 

  25. Lim J, Rietveld A, De Bleecker JL, Badrising UA, Saris CGJ, van der Kooi AJ, et al. Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy. Neurol Neuroimmunol Neuroinflammation. 2019;6(1):e513.

    Article  Google Scholar 

  26. Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, Corse AM, Mammen AL. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol. 2015;42(8):1448–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Miller FW, Cooper RG, Vencovsky J, Rider LG, Danko K, Wedderburn LR, et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum. 2013;65(12):3239–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O’Callaghan A, Martinez-Gomez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523–32.

    Article  CAS  PubMed  Google Scholar 

  29. Aussy A, Freret M, Gallay L, Bessis D, Vincent T, Jullien D, et al. The IgG2 isotype of anti-transcription intermediary factor 1-gamma autoantibodies is a biomarker of mortality in adult dermatomyositis. Arthritis Rheumatol. 2019;71:1360.

    Article  CAS  PubMed  Google Scholar 

  30. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum. 2013;65(11):2954–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res. 2017;69(11):1771–6.

    Article  CAS  Google Scholar 

  32. Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF. Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res. 2017;69(12):1909–14.

    Article  CAS  Google Scholar 

  33. Pinal-Fernandez I, Casal-Dominguez M, Pak K, Hosono Y, Huapaya J, Huang W, Albayda J, Tiniakou E, Paik J, Johnson C, Danoff SK, Corse AM, Christopher-Stine L, Mammen AL. More prominent muscle involvement in those dermatomyositis patients with anti-Mi2 autoantibodies. Neurology. 2019;93(19):e1768-e1777.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193–200.

    Article  CAS  PubMed  Google Scholar 

  35. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25–34.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW, International Myositis Collaborative Study G. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum. 2003;48(8):2285–93.

    Article  PubMed  Google Scholar 

  37. Love LA, Weinberg CR, McConnaughey DR, Oddis CV, Medsger TA Jr, Reveille JD, et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum. 2009;60(8):2499–504.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Zaraa IR, Labbène I, Mrabet D, Zribi H, Chelly I, Zitouna M, Mokni M, Sellami S, Ben Osman A. Simvastatin-induced dermatomyositis in a 50-year-old man. BMJ Case Rep 2011. pii: bcr0220113832.

    Google Scholar 

  39. Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019;381(3):291–3.

    Article  PubMed  Google Scholar 

  40. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57(5):664–78.

    Article  CAS  PubMed  Google Scholar 

  41. Wong D, Kea B, Pesich R, Higgs BW, Zhu W, Brown P, et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One. 2012;7(1):e29161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007;56(11):3784–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13(1–2):59–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Ladislau L, Suarez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018;141(6):1609–21.

    Article  PubMed  Google Scholar 

  45. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;373(4):393–4.

    Article  CAS  PubMed  Google Scholar 

  46. Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff SK, et al. Clinical profile of anti-PL-12 autoantibody: cohort study and review of the literature. Chest. 2009;135:1550.

    Article  CAS  PubMed  Google Scholar 

  47. Mescam-Mancini L, Allenbach Y, Hervier B, Devilliers H, Mariampillay K, Dubourg O, et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain J Neurol. 2015;138(Pt 9):2485–92.

    Article  Google Scholar 

  48. Stenzel W, Preusse C, Allenbach Y, Pehl D, Junckerstorff R, Heppner FL, et al. Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. Neurology. 2015;84(13):1346–54.

    Article  CAS  PubMed  Google Scholar 

  49. Chinoy H, Adimulam S, Marriage F, New P, Vincze M, Zilahi E, et al. Interaction of HLA-DRB1∗03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann Rheum Dis. 2012;71(6):961–5.

    Article  CAS  PubMed  Google Scholar 

  50. Schiffenbauer A, Faghihi-Kashani S, O’Hanlon TP, Flegel WA, Adams SD, Targoff IN, et al. The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. Semin Arthritis Rheum. 2018;48(3):504–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Plotz P, Miller FW, Milisenda JC, Grau-Junyent JM, Selva-O'Callaghan A, Paik J, Albayda J, Christopher-Stine L, Lloyd TE, Corse AM, Mammen AL. Identification of distinctive interferon gene signatures in different types of myositis. Neurology. 2019;93(12):e1193–e1204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56(9):3125–31.

    Article  CAS  PubMed  Google Scholar 

  53. Katsumata Y, Ridgway WM, Oriss T, Gu X, Chin D, Wu Y, et al. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun. 2007;29(2–3):174–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol. 2019;15(5):257–72.

    Article  PubMed  Google Scholar 

  55. Larman HB, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013;73(3):408–18.

    Article  PubMed  CAS  Google Scholar 

  56. Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ, et al. Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;73(3):397–407.

    Article  CAS  PubMed  Google Scholar 

  57. Goyal NA, Cash TM, Alam U, Enam S, Tierney P, Araujo N, et al. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. J Neurol Neurosurg Psychiatry. 2016;87(4):373–8.

    Article  CAS  PubMed  Google Scholar 

  58. Lilleker JB, Rietveld A, Pye SR, Mariampillai K, Benveniste O, Peeters MT, et al. Cytosolic 5′-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Ann Rheum Dis. 2017;76(5):862–8.

    Article  CAS  PubMed  Google Scholar 

  59. Greenberg SA, Pinkus JL, Amato AA, Kristensen T, Dorfman DM. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain J Neurol. 2016;139(Pt 5):1348–60.

    Article  Google Scholar 

  60. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology. 2008;70(6):418–24.

    Article  PubMed  Google Scholar 

  61. Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, Maisonobe T, et al. Long-term observational study of sporadic inclusion body myositis. Brain J Neurol. 2011;134(Pt 11):3176–84.

    Article  Google Scholar 

Download references

Funding

This work was supported by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health.

Author information

Authors and Affiliations

  1. Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Expression, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA

    Andrew L. Mammen

Authors
  1. Andrew L. Mammen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew L. Mammen .

Editor information

Editors and Affiliations

  1. Hartford Hospital, University of Connecticut, Hartford, CT, USA

    Paul D. Thompson

  2. Hartford Hospital, University of Connecticut, Hartford, CT, USA

    Beth A. Taylor

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mammen, A.L. (2020). Statin-Associated Autoimmune Myopathy and Other Forms of Myositis. In: Thompson, P., Taylor, B. (eds) Statin-Associated Muscle Symptoms. Contemporary Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-33304-1_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-33304-1_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-33303-4

  • Online ISBN: 978-3-030-33304-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation